Stocks
Viveve Medical Financial Statements (VIVE) |
||||||||||
| Viveve Medicalsmart-lab.ru | % | 2019 | 2019 | 2019 | 2020 | 2021 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.03.2020 | 18.06.2020 | 29.06.2020 | 18.03.2021 | 17.03.2022 | 10.11.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 6.57 | 6.57 | 6.57 | 5.48 | 6.43 | 6.83 | |||
| Operating Income, bln rub | -29.9 | -29.9 | -29.9 | -18.5 | -21.6 | -21.1 | ||||
| EBITDA, bln rub | ? | -28.9 | -28.9 | -30.7 | -18.5 | -20.6 | -20.6 | |||
| Net profit, bln rub | ? | -46.7 | -46.7 | -46.7 | -21.2 | -22.0 | -23.9 | |||
| OCF, bln rub | ? | -31.2 | -31.2 | -31.2 | -15.2 | -12.9 | -16.2 | |||
| CAPEX, bln rub | ? | 1.09 | 1.09 | 1.09 | 0.781 | 0.456 | 0.595 | |||
| FCF, bln rub | ? | -32.3 | -32.3 | -32.3 | -16.0 | -13.3 | -16.8 | |||
| Dividend payout, bln rub | 0.378 | 0.378 | 0.378 | 0.000 | 0.000 | 4.69 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -19.6% | ||||
| OPEX, bln rub | 31.0 | 31.0 | 31.0 | 18.8 | 22.2 | 22.3 | ||||
| Cost of production, bln rub | 5.55 | 5.55 | 5.55 | 5.18 | 5.81 | 5.71 | ||||
| R&D, bln rub | 8.59 | 8.59 | 8.59 | 5.13 | 9.67 | 8.72 | ||||
| Interest expenses, bln rub | 4.35 | 4.35 | 4.35 | 0.910 | 1.000 | 1.11 | ||||
| Assets, bln rub | 27.0 | 27.0 | 27.0 | 16.6 | 25.9 | 12.2 | ||||
| Net Assets, bln rub | ? | 16.5 | 16.5 | 16.5 | 6.97 | 15.1 | 1.18 | |||
| Debt, bln rub | 4.25 | 4.25 | 4.25 | 5.86 | 5.35 | 5.88 | ||||
| Cash, bln rub | 13.3 | 13.3 | 13.3 | 6.52 | 19.2 | 5.91 | ||||
| Net debt, bln rub | -9.06 | -9.06 | -9.06 | -0.66 | -13.8 | -0.03 | ||||
| Ordinary share price, rub | 12.6 | 12.6 | 12.6 | 4.70 | 1.14 | 0.907 | ||||
| Number of ordinary shares, mln | 0.125 | 0.125 | 0.125 | 1.57 | 10.1 | 10.7 | ||||
| Market cap, bln rub | 2 | 2 | 2 | 7 | 12 | 10 | ||||
| EV, bln rub | ? | -7 | -7 | -7 | 7 | -2 | 10 | |||
| Book value, bln rub | 17 | 17 | 17 | 7 | 15 | 1 | ||||
| EPS, rub | ? | -374.4 | -374.4 | -374.4 | -13.5 | -2.18 | -2.24 | |||
| FCF/share, rub | -259.0 | -259.0 | -259.0 | -10.2 | -1.32 | -1.58 | ||||
| BV/share, rub | 132.4 | 132.4 | 132.4 | 4.43 | 1.49 | 0.11 | ||||
| EBITDA margin, % | ? | -440.3% | -440.3% | -467.2% | -337.6% | -320.8% | -301.4% | |||
| Net margin, % | ? | -711.4% | -711.4% | -711.4% | -387.6% | -342.8% | -350.4% | |||
| FCF yield, % | ? | -2 056% | -2 056% | -2 056% | -216.5% | -115.9% | -174.0% | |||
| ROE, % | ? | -282.8% | -282.8% | -282.8% | -304.5% | -146.2% | -2 020% | |||
| ROA, % | ? | -173.2% | -173.2% | -173.2% | -127.7% | -85.0% | -196.8% | |||
| P/E | ? | -0.03 | -0.03 | -0.03 | -0.35 | -0.52 | -0.40 | |||
| P/FCF | -0.05 | -0.05 | -0.05 | -0.46 | -0.86 | -0.57 | ||||
| P/S | ? | 0.24 | 0.24 | 0.24 | 1.35 | 1.79 | 1.42 | |||
| P/BV | ? | 0.10 | 0.10 | 0.10 | 1.06 | 0.76 | 8.17 | |||
| EV/EBITDA | ? | 0.26 | 0.26 | 0.24 | -0.36 | 0.11 | -0.47 | |||
| Debt/EBITDA | 0.31 | 0.31 | 0.30 | 0.04 | 0.67 | 0.00 | ||||
| R&D/CAPEX, % | 790.2% | 790.2% | 790.2% | 656.2% | 2 120% | 1 466% | ||||
| CAPEX/Revenue, % | 16.6% | 16.6% | 16.6% | 14.3% | 7.10% | 8.72% | ||||
| Viveve Medical shareholders | ||||||||||
